Prelude Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,300
Closed -$122K – 1562
2026
Q2
$122K Sell
11,300
-34,770
-75% -$315K 0.01% 1083
2026
Q1
$584K Buy
+46,070
New +$523K 0.04% 452
2025
Q4
– Sell
-33,037
Closed -$396K – 1485
2025
Q3
$396K Buy
+33,037
New +$348K 0.03% 588
2023
Q1
– Sell
-15,353
Closed -$90.4K – 1383
2022
Q4
$90.4K Buy
15,353
+143
+0.9% +$483 ﹤0.01% 1088
2022
Q3
$49K Sell
15,210
-1,090
-7% -$4.36K ﹤0.01% 1232
2022
Q2
$73K Buy
+16,300
New +$65K ﹤0.01% 1456

Other funds holding ORIC

Prelude Capital Management's ORIC Position: Q3 2026 in Review

Prelude Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q3 2026, closing a stake of 11,300 shares — an estimated $122K sold.

Prelude Capital Management first reported a position in ORIC in Q2 2022 and held it in 6 quarters. The position peaked at $584K in Q1 2026. 203 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

  • Prelude Capital Management reported no remaining Oric Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Prelude Capital Management sold 11,300 Oric Pharmaceuticals shares in Q3 2026, an estimated $122K.
  • Prelude Capital Management first reported a position in Oric Pharmaceuticals in Q2 2022 and held it in 6 quarters.
  • Prelude Capital Management's Oric Pharmaceuticals position peaked at $584K in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.